epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
16 May – Greggs reaches a deal with Westminster City Council to allow it to sell food and hot drinks at its Leicester Square outlet until 2.00am on some nights. The council had objected to a previous plan for 24-hour opening amid concerns it would attract antisocial behaviour, with the agreement reached as a court case was about to commence. 17 May – The £2 cap on bus fares in England is extended until the end of October; a £2.50 cap will then be in place until December 2024. 18 May – Two teenage cousins are sentenced to life imprisonment for the murder of Khayri Mclean, who was stabbed in Huddersfield, West Yorkshire in 2022 as he walked home from school. 22 May – After the latest round of talks with the government end without resolution, the British Medical Association announces that junior doctors will stage another 72-hour strike, scheduled to begin on 14 June. 23 May – Samantha Lee, a former Metropolitan Police constable who failed to properly investigate two counts of indecent exposure committed by Wayne Couzens, is found guilty of gross misconduct following a hearing. David Boyd is sentenced to life imprisonment with a minimum term of 29 years for the 1992 murder of Nikki Allan. 25 May – The UK Health Security Agency urges people at risk of contracting the Mpox virus to get vaccinated after 10 new cases were discovered in London between 30 April and 25 May.
There are number of articles, columns, and interviews in LCGC relating to emerging trends in chiral analysis and its application in drug discovery and development process. For chiral examination there is a need to have the right chiral environment. This could be provided as a plane polarized light, an additional chiral compound or by exploiting the inborn chirality of nature. The chiral analytical strategies incorporate physical, biological, and separation science techniques. Recently an optical-based absolute chiral analysis has been reported. The most frequently employed technique in enantioselective analysis involve the separation science techniques, in particular chiral chromatographic methods or chiral chromatography. Today wide range of CSPs are available commercially based on various chiral selectors including polysaccharides, cyclodextrins, glycopeptide antibiotics, proteins, Pirkle, crown ethers, etc. to achieve analysis of chiral molecules.
In Switzerland, a maximum radiation exposure of 1 mSv per year and a maximum of 5 mSv per year for the patient's relatives may not be exceeded. After discharge following radioiodine therapy, a maximum dose rate of 5 μSv per hour at a distance of 1 meter is permitted, which corresponds to a residual activity of approximately 150 MBq. In the event of early discharge, the supervisory authority must be notified up to a dose rate of 17.5 μSv/h; above 17.5 μSv/h, permission must be obtained. If the patient is transferred to another ward, the responsible radiation protection officer must ensure that appropriate radiation protection measures are taken there, e.g. that a temporary control area is set up.
HVEC's first product line targeted cancer treatment, an application that demonstrated the practical value of controlled particle acceleration for medicine. Between 1948 and 1969, the company manufactured compact 2-megavolt electron accelerators designed for hospital radiotherapy departments. These 8-foot-long generators could be operated by technicians and nurses, making radiation therapy accessible beyond major research hospitals. During their production run, 35 U.S. hospitals and eight hospitals abroad installed the machines for cancer treatment. The generators addressed significant limitations in available cancer treatments. Traditional radiotherapy relied on radium sources, which were expensive, scarce, and produced uncontrolled radiation that damaged healthy tissue surrounding tumors. Low-voltage (0.25 MV) x-ray devices were available, but lacked sufficient penetration to treat deep tumors and caused violent skin reactions. HVEC's 1- and 2-MV Van de Graaff accelerators generated artificial X-rays that could be precisely aimed and modulated, allowing physicians to target deep-seated tumors while minimizing exposure to surrounding organs. The beam energy could be adjusted to match tumor depth, and therapy could be spread across multiple sessions to reduce side effects. HVEC also supported medical research.
Sources: en.wikipedia.org
These oligosaccharides are used in combination to improve the beneficial gut bacteria while eliminating the harmful gut bacteria. The aging dog goes through changes in brain and cognitive health. There are two highly important ingredients that can be included in senior dog foods to help prevent cognitive decline and improve brain health. These ingredients are vitamin E and L-carnitine. Vitamin E acts as an antioxidant, which can prevent oxidative damage that occurs during aging. L-carnitine is used to improve mitochondrial function, which can also help to prevent and lower rates of oxidative damage. Skin and coat health is important in all dogs, but especially becomes important as dogs age. An important nutrient to look for in senior dog foods to support coat health is linoleic acid, which can be found in corn and soybean oil. Another important nutrient is vitamin A, which helps with keratinization of hair. Good sources of vitamin A for skin and coat health include egg yolk and liver. Immune system health has been shown to decline in aging dogs. The ratio of omega-6 to omega-3 fatty acids plays an important role in providing optimal health. Vitamin E can be used as an antioxidant in senior dog foods. Pre- and probiotics can also be added to senior dog foods to help improve the beneficial bacteria in the gut, providing support for the immune system.
=== Cancer === A meta-analysis concluded that supplementation with β-carotene does not appear to decrease the risk of cancer overall, nor specific cancers including: pancreatic, colorectal, prostate, breast, melanoma, or skin cancer generally. High levels of β-carotene may increase the risk of lung cancer in current and former smokers. Results are not clear for thyroid cancer.
The major surviving part of the walls is visible adjacent to the only remaining gateway under the tower of the Church of St John the Baptist. By the mid-14th century Bristol is considered to have been England's third-largest town (after London and York), with an estimated 15–20,000 inhabitants on the eve of the Black Death of 1348–49. The plague inflicted a prolonged demographic setback, with the population estimated at between 10,000 and 12,000 during the 15th and 16th centuries. One of the first great merchants of Bristol was William Canynge. Born c. 1399, he was five times mayor of the town and twice represented it as an MP. He is said to have owned ten ships and employed over 800 sailors. In later life he became a priest and spent a considerable part of his fortune in rebuilding St Mary Redcliffe church, which had been severely damaged by lightning in 1446.
=== Psychological mechanisms and adherence === As self-management of diabetes typically involves lifestyle modifications, adherence may pose a significant self-management burden on many individuals. For example, individuals with diabetes may find themselves faced with the need to self-monitor their blood glucose levels, adhere to healthier diets and maintain exercise regimens regularly in order to maintain metabolic control and reduce the risk of developing cardiovascular problems. Barriers to adherence have been associated with key psychological mechanisms: knowledge of self-management, beliefs about the efficacy of treatment and self-efficacy/perceived control. Such mechanisms are inter-related, as one's thoughts (e.g. one's perception of diabetes, or one's appraisal of how helpful self-management is) is likely to relate to one's emotions (e.g. motivation to change), which in turn, affects one's self-efficacy (one's confidence in their ability to engage in a behaviour to achieve a desired outcome). As diabetes management is affected by an individual's emotional and cognitive state, there has been evidence suggesting the self-management of diabetes is negatively affected by diabetes-related distress and depression. There is growing evidence that there is higher levels of clinical depression in patients with diabetes compared to the non-diabetic population. Depression in individuals with diabetes has been found to be associated with poorer self-management of symptoms. This suggests that it may be important to target mood in treatment.
== Organization and affiliations == Einstein comprises 30 academic departments, spanning clinical care and both basic and translational research. The college's chief academic officer is the Marilyn and Stanley M. Katz Dean, a position held by Yaron Tomer since 2023. The Board of Trustees consists of three officers—Chair Ruth Gottesman, treasurer Nathan Gantcher, and Montefiore Einstein CEO and President Philip Ozuah as of 2025—and 28 members.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.